Researchers evaluated the effects of poor sleep and low heart rate variability on the odds of metabolic syndrome.
All articles by Dee Rapposelli
A phase 2 clinical trial examined the efficacy of treating painful diabetic neuropathy (PDN) with filorexant, an orexin receptor antagonist.
Publish Date
-
Latest News Your top articles for Saturday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses